Homing in on a moving target: Androgen Receptor cistromic plasticity in prostate cancer.


The androgen receptor (AR) is the critical driver in prostate cancer and exerts its function mainly through transcriptional control. Recent advances in clinical studies and cell line models, illustrated that AR chromatin binding features are not static, but rather highly variable yet reproducibly altered between clinical stages. Extensive genomic analyses of AR chromatin binding features in different disease stages, revealed a high degree of plasticity of AR chromatin interactions in clinical samples. Mechanistically, AR chromatin binding patterns are associated with specific somatic mutations on AR and other permutations including mutations of AR-interacting proteins. Here we summarise the most recent studies on how the AR cistrome is dynamically altered in prostate cancer models and patient samples, and which implications this has for the identification of therapeutic targets to avoid the emergence of treatment resistance.

More about this publication

  • Publication date 20-09-2022

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.